Lies Remeijer

Lies Remeijer

Auto-generated profile, based on publicly available information

Lies Remeijer

Cornea and External Diseases Department, Rotterdam Eye Hospital, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2026 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
ARAnna Randag
Anna Randag
GVGeorges Mgm Verjans
Georges Mgm Verjans
LRLies Remeijer
Lies Remeijer
Herpes simplex virus type 1 (HSV-1), one of the human herpesviruses, is a frequent cause of recurrent ocular infections. Treatment primarily relies on nucleoside analogues, such as aciclovir (ACV), with or without topical corticosteroids. Treatment failure may be attributed to non-adherence to therapy or inadequate topical corticosteroid dosing, and to a lesser extent to an incorrect diagnosis, coinfection with non-viral pathogens or therapy resistance. ACV resistance (ACV R ) is relatively rare compared with other reasons for treatment failure, but has been documented in 6% of immunocompetent patients with HSV-1 keratitis. ACV R limits the prophylactic and therapeutic efficacy of nucleoside analogues, potentially leading to clinically refractory disease. In this review, we will address the normal pathogenesis of HSV-1 keratitis, the definition and causes of treatment failure in HSV-1 keratitis, a work-up algorithm to be used in the event of treatment failure, the effect of current treatment regimens on the development of ACV R keratitis and treatment options for ACV R keratitis.